Pharmacy Express Health-B: The first patient in the Phase II clinical trial of Temozolomide combined with Kaitanni/Idafang has been dosed.

Yaojie Ankang-B Announcement: The Phase II clinical study of the company's core product, the combination therapy of Tengeneitinib/Erdafitinib with Kangfangbiotech's Okatinib, for the treatment of advanced hepatocellular carcinoma has completed the first patient dosing. This trial aims to evaluate the safety and effectiveness of combination therapy, with the main target population being advanced hepatocellular carcinoma patients who have not received systemic anti-tumor therapy for hepatocellular carcinoma or have failed standard treatment in the past.